Middle East and Africa White Biotech Market Report

To learn more about this report, Download Free Sample Report

Middle East and Africa White Biotech Market Size

The Middle East and Africa white biotech market size was valued at USD 14.79 billion in 2025 and is projected to reach USD 33.25 billion by 2034 from USD 16.18 billion in 2026, growing at a CAGR of 9.42%.

The technology related to life is called biotechnology. This technology is made up of human knowledge and skills. Biotechnology is established on the application of scientific and engineering principles. White biotechnology is also called industrial biotechnology. This technology uses enzymes and microorganisms to develop bio-based products that are used in various industries, including bioenergy, beauty and personal care, chemicals, food and feed, home care, and pharmaceuticals. End users in developing and underdeveloped regions are not very aware of the day-to-day benefits of white biotech-based products and the detrimental effects of greenhouse gas emissions from non-biologically based products.

Crude oil is the most important source of energy, as many industries depend on the use of chemicals derived from crude oil. However, the lack of oil reserves and environmental concerns have led to the need to develop sustainable methods to produce these chemicals. White biotechnology enables such materials to be produced from renewable sources. It offers substantial advantages over conventional methods. Biofuels are fuels produced from biomass. Biomass is organic material produced from animals and plants. Includes wood, crops and agricultural products, aquatic plants, forest products, waste and residues and animal waste. Biofuels can be used as substitutes for jet fuel. This helps reduce GHG emissions, promoting its adoption worldwide. Enzymatic technology is one of the most important technologies used in industrial processes. Protein engineering has improved the development of industrial enzymes because it uses recombinant technology to produce enzymes with new activities that easily adapt to new processes. Enzyme manufacturing involves recombinant expression in specific host organisms such as bacteria and yeast, fermentation, recovery, and formulation. Enzymes are implemented in the pulp, paper and textile industries for its applications like softening of wooden fibers and promote drainage. Enzymes are a sustainable alternative to aggressive chemicals used in industries. In fact, they are suitable for working in moderate conditions, such as hot temperatures and neutral potential of hydrogen (pH).

MARKET SEGMENTATION

This research report on the Middle East and Africa white biotech market has been segmented and sub-segmented based on the following categories.

By Product                    

• Biochemicals          
• Biomaterials           
• Biofuels    

By Application                            

• Personal Care & Household Products          
• Pharmaceutical Ingredients             
• Food & Feed Additives      
• Bioenergy

By Country

•  South Africa
• Egypt
• Saudi Arabia
• United Arab Emirates
• Israel

Middle East and Africa is one of the key emerging regions, which will generate significant opportunities in the Middle East and Africa White Biotech market during the forecast period due to the to increasing number of chemical industries. Bioethanol is largely manufactured using white biotechnology. It is primarily used as a fuel to improve vehicle efficiency and as a gasoline additive to improve a vehicle's octane number. Growth in the automotive sector, primarily in Germany, is expected to fuel the needs of the process during the forecast period.

KEY MARKET PLAYERS

• Corbion
• DuPont
• Archer Daniels Midland Co.
• DSM
• BASF SE
• Novozymes
• Cargill Inc

RECENT HAPPENINGS IN THE MARKET

• Kaneka signed a collaboration agreement with Terumo BCT Inc. to request clinical trials in the United States for its new LDL absorption system. Additionally, the Spectra Optia system can be found in hospitals across the United States, so, unlike the current situation, it will not be necessary to bring specialized devices or train hospital staff in the use of the device.
• Ra Pharmaceuticals (RARX) Shares doubled after Belgian Biotech Company UCB announced it was buying the biotech company for $ 2.1 billion in cash.
• Gilead has announced plans to acquire nearly half of the Pionyr anticancer biotechnology, with an exclusive option to acquire the rest of the company as the large pharmaceutical company continues to expand in oncology. California-based Gilead said it purchased a 50.0% stake in privately owned Pionyr Immunotherapeutics for $ 276 million.
• Servier has signed a definitive agreement to acquire Symphogen A/S antibody discovery biotechnology. This acquisition, the result of a process that has been ongoing for several months, will strengthen Servier's antibody capabilities and ensure that the platform for the development of Symphogen early and antibody discovery are fully utilized.
• French pharmacist Sanofi agreed to buy Belgian biotech company Ablynx for € 3.9 billion ($ 4.8 billion), beating Novo Nordisk and achieving its second big deal after buying Bioverativ.
• TWB and Hamilton signed a partnership deal for a tenure of 18 months to develop an innovative bioprocessing platform that will be crucial for the in-depth characterization and optimization of microorganism culture. This platform, with 24 integrated mini-reactors (50 ml), will greatly accelerate the process of developing industrial bioprocess solutions.
• White Biotech BRAIN AG has purchased specific gene-based industrial biotechnology assets from MerLion Pharmaceuticals GmbH.
• Pfizer paid $ 3.6 billion for King Pharmaceuticals, a far cry from its 2009 acquisition of Wyeth, on which it spent $ 68 billion. Pfizer, like Novartis, is no stranger to major mergers; in 2000, he gave Warner Lambert $ 89 billion.